Navigation Links
UGA study suggests key to avoiding ankle re-injury may be in the hips and knees
Date:10/17/2011

en than either of the other groups. However, the "copers" also showed differences in those joint movements. The injured group with lingering ankle pain appeared unable to use their knee and hip joints as well when landing on the metal surface.

"Maybe the injured people don't use the same landing strategies, or their strategies aren't as effective," Brown said, adding that the study was a snapshot in time, not a long-term follow-up. By the time subjects were included in the research study, they have usually already injured themselves. "We don't know if they are this way because of the injury, or if they got this injury because they land this way."

The current study looked at the knees, hips and ankles in isolation, and the next step for the team will be to examine the joints in combination. If future studies allow the researchers to identify particular movement patterns as helpful, the research could be directly translated into new techniques for rehabilitation therapists and the public in general.

Brown said the current study builds on a similar study published in June 2011 that examined ankle injuries based on the amount of clearance between the foot and the ground. In that study, she found that participants with previous ankle injuries kept their feet closer to the ground, with their toes pointing downward, while running.

"I always try to encourage people who are having a lot of problems with their ankle to see a health care professional who would be able to help them," she said. "There are negative long-term consequences to ankle instability, such as ankle osteoarthritis, that may be preventable with treatment."


'/>"/>

Contact: Cathleen Brown
browncn@uga.edu
706-542-9257
University of Georgia
Source:Eurekalert

Page: 1 2

Related biology news :

1. Genetic study of cave millipedes reveals isolated populations and ancient divergence between species
2. Study shows that new DNA test to identify Down syndrome in pregnancy is ready for clinical use
3. Study shows unexpected effect of climate change on body size for many different species
4. Joslin study finds clue to birth defects in babies of mothers with diabetes
5. First genome-wide association study for dengue identifies candidate susceptibility genes
6. Largest ever genetic study of liver function could point the way to new treatments
7. Study reveals new role for RNA interference during chromosomal replication
8. Method of studying roots rarely used in wetlands improves ecosystem research
9. Southampton scientists herald significant breakthrough in study of chlamydia
10. Einstein College of Medicine given $6.7 million to study congenital heart defect genetics
11. National Science Foundation selects University of Colorado Denver team to study city sustainability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2015)... NexID Biometrics LLC, whose spoof-mitigation technology boosts protection ... beginning of shipments of version 2.0 of its industry ... in Potsdam, N.Y. , is making ... here today at the Walter E. Washington Convention Center. ... boosts the accuracy rate range to 96.5 to 99.5 ...
(Date:3/23/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet, ... March 30 th . The new ... York markets. Gino Pereira ... new ad campaign following the recent initial shipment of Wocket ...
(Date:3/19/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces its biometric payment technology, the Wocket® smart ... week on Washington DC,s Fox 5 ... "The Next Great Thing", host Laura Evans calls ... ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... Institutet have identified an important mechanism that regulates how ... cell. The study is published in the latest issue ... help us develop new drugs for things like neurological ... most organs of the body, old cells are continually ...
... To a tiny tadpole, life boils down to two basic ... The more a tadpole eats, the faster it grows big ... being active, which ups the odds of becoming someone else's ... activity levels in response to predation risk, but new research ...
... discovered how the brain creates a scent symphony from signals ... researchers found that nerve cells in the brain's olfactory bulb ... do not perceive complex scent mixtures as single objects, such ... cells, or neurons, detect the host of chemical compounds that ...
Cached Biology News:New stem-cell findings can help the body to cure itself 2Time of day tempers tadpoles' response to predators 2Researchers show how brain decodes complex smells 2
(Date:4/21/2015)... April 21, 2015 Ampio Pharmaceuticals, Inc. (NYSE ... investor call on Thursday, April 23, 4:30 p.m. ET. ... as follows: Investor call information: ... 789-4877 International toll number: (925) 418-7845 Participant Passcode: 32888538 ... Tina Amirkiai , tina.amirkiai@fleishman.com . ...
(Date:4/21/2015)... , April 21, 2015  Cryoport, ... of advanced cryogenic logistics solutions for the ... stem cells, cell lines, clinical research organizations, ... that Dr. Mark W. Sawicki , ... 3rd Annual BioLogistics Summit in San ...
(Date:4/21/2015)... April 21, 2015  scPharmaceuticals, Inc., a ... products for subcutaneous delivery, announced today that ... its investigational proprietary drug product, Furosemide Injection ... with congestive heart failure. Concurrently ... a proprietary patch pump.  The patch pump ...
(Date:4/21/2015)... Bruno, CA (PRWEB) April 21, 2015 ... CRO, will sponsor and exhibit at the ACRP 2015 ... Salt Lake City, Utah. The Association of Clinical Research ... annual clinical research conference solely focused on the conduct ... membership, training and development, and widely recognized industry certifications. ...
Breaking Biology Technology:Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 3scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 2scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 3PRC Clinical Sponsors The ACRP 2015 Global Conference And Meets Biotech Companies in the Salt Lake City Area. 2
... NOVATO, Calif., June 1 Raptor Pharmaceuticals Corp. ... today announced that it has dosed the first ... in collaboration with the University of California, ... delayed-release cysteamine bitartrate ("DR Cysteamine") capsules in nephropathic ...
... ... Mass Spectrometry-based biomarker discovery will be demonstrated at the 57th ASMS Conference on Mass ... , ... (PRWEB) June 1, 2009 -- Genedata , a leading provider of in silico ...
... from the first time point measured (1.5 hours) through ... Shire plc (LSE: SHP, Nasdaq: ... announced that the US Food and Drug Administration (FDA) ... its once-daily Attention Deficit Hyperactivity Disorder (ADHD) treatment VYVANSE ...
Cached Biology Technology:Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 2Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 3Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 4Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 5Genedata Launches Expressionist with Expanded Mass Spectrometry Biomarker Discovery Capabilities 2Genedata Launches Expressionist with Expanded Mass Spectrometry Biomarker Discovery Capabilities 3FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 2FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 3FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 4FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 5FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 6FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 7